Wickström S A, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo K, Keski-Oja J
Cell Biology and Molecular/Cancer Biology Laboratories, Biomedicum Helsinki, University of Helsinki, FIN-00014 Helsinki, Finland.
Cancer Res. 2001 Sep 1;61(17):6511-6.
Endostatin, a M(r) 20,000 fragment of collagen XVIII, is able to inhibit angiogenesis and induce apoptosis in endothelial cells in vivo. We analyzed the effectsof recombinant endostatin on human microvascular endothelial cells, focusing on pericellular plasminogen activation and its targeting by the focal adhesion-associated cytoskeletal structures. Analysis of the proteolytic plasminogen activator system revealed that endostatin modulates the distribution of soluble and cell surface-associated urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor, type 1 (PAI-1). Casein zymographic and immunoprecipitation analyses indicated that endostatin exerts its effects by decreasing the levels of soluble uPA and PAI-1 and their complexes in a dose-dependent manner. Immunofluorescence analysis of cell surface-associated uPA indicated that endostatin treatment caused the redistribution of receptor-bound uPA from focal contacts, resulting in diffuse cell surface staining. In accordance with this observation, immunofluorescence staining of the urokinase receptor revealed that endostatin treatment removed uPAR from focal adhesions. Accordingly, endostatin caused a rapid disassembly of focal adhesions as observed by immunofluorescence analysis of the focal adhesion proteins vinculin and paxillin. A prominent change in the cytoskeletal architecture was observed as the actin stress fiber network was dissociated in response to endostatin treatment. The effect of focal adhesion disassembly was reversible, persisting from 1 h up to 6 h. Our results suggest that the antiangiogenic activity of endostatin involves the modulation of focal adhesions and actin stress fibers and the down-regulation of the urokinase plasminogen activator system.
内皮抑素是胶原蛋白 XVIII 的一个分子量为 20,000 的片段,能够在体内抑制血管生成并诱导内皮细胞凋亡。我们分析了重组内皮抑素对人微血管内皮细胞的影响,重点关注细胞周围纤溶酶原激活及其被黏着斑相关细胞骨架结构靶向的情况。对蛋白水解性纤溶酶原激活系统的分析表明,内皮抑素可调节可溶性和细胞表面相关的尿激酶型纤溶酶原激活剂(uPA)及纤溶酶原激活剂抑制剂 1 型(PAI-1)的分布。酪蛋白酶谱分析和免疫沉淀分析表明,内皮抑素通过以剂量依赖的方式降低可溶性 uPA 和 PAI-1 及其复合物的水平来发挥作用。对细胞表面相关 uPA 的免疫荧光分析表明,内皮抑素处理导致受体结合的 uPA 从黏着斑重新分布,从而使细胞表面出现弥漫性染色。与这一观察结果一致,尿激酶受体的免疫荧光染色显示,内皮抑素处理使 uPAR 从黏着斑上移除。因此,如通过对黏着斑蛋白纽蛋白和桩蛋白的免疫荧光分析所观察到的,内皮抑素导致黏着斑迅速解体。随着肌动蛋白应力纤维网络因内皮抑素处理而解离,观察到细胞骨架结构发生了显著变化。黏着斑解体的效应是可逆的,持续时间从 1 小时到 6 小时。我们的结果表明,内皮抑素的抗血管生成活性涉及对黏着斑和肌动蛋白应力纤维的调节以及尿激酶纤溶酶原激活系统的下调。